Abstracts tagged "giant cell arteritis"

Abstract Number: 0418 • ACR Convergence 2020
Prevalence of Thyroid Disease Among Patients with Vasculitis
Tanaz Kermani¹, David Cuthbertson², Simon Carette³, Nader Khalidi⁴, Curry L. Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Ulrich Specks¹², Antoine Sreih¹³, Kenneth Warrington¹² and Peter Merkel¹³, ¹David Geffen School of Medicine / University of California, Los Angeles, CA, ²University of South Florida, Tampa, ³Division of Rheumatology, Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Utah, Salt Lake City, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Pennsylvania, Philadelphia, ⁸Brigham and Women's, Boston, ⁹University of Pittsburgh, Denver, CO, ¹⁰Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, Rochester, MN, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Previous studies have reported higher risk of thyroid disease in patients with giant cell arteritis (GCA) and ANCA-associated vasculitis (AAV) compared to age- and…
Abstract Number: 1919 • ACR Convergence 2020
Efficacy & Safety of Tocilizumab in Giant Cell Arteritis: A Single Centre NHS Experience Using Imaging (Ultrasound and PET CT) as a Diagnostic and Monitoring Tool
Alwin Sebastian¹, Abdul Kayani¹, Diana Prieto-Peña², Alessandro Tomelleri³, Madeline Whitlock¹, Kornelis S. M. van der Geest⁴ and Bhaskar Dasgupta¹, ¹Rheumatology, Mid and South Essex University Hospital NHS Foundation Trust, Southend University Hospital, United Kingdom, Westcliff on sea, England, United Kingdom, ²Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, Milan, Italy, ⁴Rheumatology and Clinical Immunology, University Medical Center Groningen, Netherlands, Groningen, Netherlands
Background/Purpose: Tocilizumab (TCZ), an IL-6 receptor blocker is approved to treat relapsing, refractory Giant cell arteritis (GCA) We here report our real-life clinical experience with…
Abstract Number: 1938 • ACR Convergence 2020
Risk for Vision Loss and Relapse in Patients with Giant Cell Arteritis
Anne Bull Haaversen¹ and Andreas Diamantopoulos², ¹Martina Hansens Hospital, Hosle, Norway, ²Martina Hansens Hospital, Baerum, Norway
Background/Purpose: Giant cell arteritis (GCA) involves both the cranial and large vessels. Studies have shown that while the vision loss rates are higher, the relapse…
Abstract Number: 0420 • ACR Convergence 2020
Prospective Analysis of the Prevalence of Giant Cell Arteritis in Consecutive Newly Diagnosed Patients with Polymyalgia Rheumatica
Lara Burg¹, Peter Brossart², Charlotte Behning³ and Valentin Schaefer⁴, ¹Clinic for Internal Medicine III, Department of Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ²Clinic for Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ³Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ⁴Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany
Background/Purpose: Giant cell arteritis (GCA) is the most common form of systemic vasculitis affecting people aged 50 years and older.1 Although it is known, that…
Abstract Number: 1920 • ACR Convergence 2020
Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis and Visual Impairment
Andrea Rubbert Roth¹, Scott Tschuppert², Thomas Neumann², Ulf Benecke³, Ian Pirker³ and Johannes von Kempis³, ¹Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, ²Kantonsspital St Gallen, St.Gallen, Switzerland, ³Kantonspital St Gallen, St. Gallen, Switzerland
Background/Purpose: Tocilizumab (TCZ) represents a potent new therapeutic principle for patients with GCA, however, data on efficacy and safety in patients who present with visual…
Abstract Number: 1939 • ACR Convergence 2020
Definitions and Reliability Assessment of Chronic Ultrasound Lesions of the Axillary Artery in Giant Cell Arteritis: A Study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group
Valentin Schaefer¹, Stavros Chrysidis², Greta Carrara³, Wolfgang Schmidt⁴, George A. Bruyn⁵, Bhaskar Dasgupta⁶, Eugenio De Miguel⁷, Andreas Diamantopoulos⁸, Christina Duftner⁹, Ulrich Fredberg¹⁰, Berit Nielsen¹¹, Wolfgang Hartung¹², Alojzija Hocevar¹³, Annamaria Iagnocco¹⁴, Aaron Juche⁴, Tanaz Kermani¹⁵, Tove Lorenzen¹⁶, Pierluigi Macchioni¹⁷, Marcin Milchert¹⁸, Uffe Døhn¹⁹, Sara Monti²⁰, Chetan Mukhtyar²¹, Cristina Ponte²², Carlo Scire²³, Lene Terslev²⁴, Luca Seitz²⁵ and Christian Dejaco²⁶, ¹Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ²Sydvestjysk Sygehus Esbjerg, Esbjerg, Denmark, ³Epidemiology Unit, Italian Society for Rheumatology, Milan, Italy, ⁴Immanuel Krankenhaus Berlin Buch, Berlin, Germany, ⁵Rheumatology, Reumakliniek Lelystad, Lelystad, Netherlands, ⁶Rheumatology, Mid and South Essex University Hospital NHS Foundation Trust, Southend University Hospital, United Kingdom, Westcliff on sea, England, United Kingdom, ⁷Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁸Martina Hansens Hospital, Baerum, Norway, ⁹Medical University Innsbruck, Innsbruck, Austria, ¹⁰Silkeborg Regional Hospital, Silkeborg, Denmark, ¹¹Aarhus University Hospital, Aarhus, Denmark, ¹²Asklepios Klinik Bad Abbach, Bad Abbacg, Germany, ¹³University Medical Center, Rheumatology, Ljubljana, LJUBLJANA, Slovenia, ¹⁴Università degli Studi di Torino, Academic Rheumatology Centre, Turin, Italy, ¹⁵David Geffen School of Medicine / University of California, Los Angeles, CA, ¹⁶Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ¹⁷Unità Operativa di Reumatologia/Arcispedale S. Maria Nuova, Reggio Emilia, Italy, ¹⁸Pomeranian Medical University, Szczecin, Poland, ¹⁹Center for Rheumatology and Spine Diseasesand COPECARE, Copenhagen, Denmark, ²⁰Fondazione IRCCS Policlinico S Matteo, University of Pavia, Pavia, Italy, ²¹Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom, ²²Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ²³University of Ferrara, Ferrara, Italy, ²⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup., Copenhagen, Denmark, ²⁵Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ²⁶South Tyrol Health Trust, Hospital of Bruneck, Bruneck, Italy
Background/Purpose: The OMERACT Ultrasound (US) large vessel vasculitis task force has recently defined the US appearance of normal axillary arteries (AA) and the key elementary…
Abstract Number: 0510 • ACR Convergence 2020
Expression and Functional Activity of the Angiotensin II System in Temporal Artery Lesions from Patients with Giant Cell Arteritis
Marco A. Alba¹, Ester Planas-Rigol², Marc Corbera-Bellalta², Nekane Terrades-García³, Ana García-Martínez³, Sergio Prieto-González¹, Roser Alba-Rovira³, Georgina Espígol-Frigolé¹, Javier Marco-Hernández¹, Jose Hernández-Rodríguez¹, Josep M Grau⁴ and Maria C. Cid¹, ¹Vasculitis Research Unit, Department of Systemic Autoimmune Diseases, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Barcelona, Catalonia, Spain, ²Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, IRB-CELLEX. Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain, Barcelona, Spain, ³Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, IRB-CELLEX. Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain, Barcelona, ⁴Department of Internal Medicine, Hospital Clínic and Fundació Cellex, University of Barcelona, Barcelona, Spain., Barcelona
Background/Purpose: Giant cell arteritis (GCA) is a large and medium size-vessel granulomatous vasculitis that predominantly affects the aorta and its major branches. The renin-angiotensin-aldosterone system…
Abstract Number: 1922 • ACR Convergence 2020
Association of Leukocyte Populations in Peripheral Blood and Arterial Wall Inflammation Assessed by FDG-PET in Takayasu’s Arteritis and Giant Cell Arteritis
K. Bates Gribbons¹, Kaitlin Quinn², Mark Ahlman³, Peter Merkel⁴ and Peter C. Grayson⁵, ¹McGovern Medical School UT Houston, Houston, TX, ²Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, ³National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD
Background/Purpose: Positron emission tomography (PET) is useful to demonstrate fluorodeoxyglucose (FDG) uptake in the large arteries in both Takayasu’s arteritis (TAK) and giant cell arteritis…
Abstract Number: 1940 • ACR Convergence 2020
In Newly Diagnosed Giant Cell Arteritis in a Real Life Setting Relapses Are Seen in More Than a Third of Patients – and Despite Faster Early Reduction High Cumulative Glucocorticoid Doses Are Reached
Laura Felten¹, Nicolai Leuchten¹ and Martin Aringer², ¹University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ²Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, Dresden, Germany
Background/Purpose: To investigate real life glucocorticoid (GC) dosing and relapse rates in patients with new onset giant cell arteritis (GCA) in a single center.Methods: Complete…
Abstract Number: 762 • 2019 ACR/ARP Annual Meeting
Are There Any Identifiable Triggers in Polymyalgia Rheumatica? A Matched-Control Study
Mayra Tobar Jaramillo¹, Victor Santos Andrade ², Marina Scolnik ³, Luciano Fernando Lo Giudice ⁴, John Jaramillo Gallego ⁵, Valeria Scaglioni ⁵ and Enrique Soriano ⁶, ¹Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Rheumatology Section, Internal Medicine Service, Fundacion Valle de lili, Colombia, Cali, Valle del Cauca, Colombia, ³Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁴Hospital Italiano de Buenos Aires, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁵Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autónoma de Buenos Aires, Argentina, ⁶Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina
Background/Purpose: As many other rheumatologic diseases, pathogenesis of Polymyalgia Rheumatica (PMR) isnot well understood. Genetic factors seem to play a role. Some studies have suggested…
Abstract Number: 2659 • 2019 ACR/ARP Annual Meeting
Giant-Cell Arteritis Associated with Myeloproliferative Neoplasms: A Retrospective Case–Control Study
Matthias Papo¹, Laure Delaval ¹, Hubert de BOYSSON ², Jean-François Viallard ³, Aurélie Foucher ⁴, Sébastien Humbert ⁵, Pierre Duffau ⁶, Anne Contis ⁷, Christian Agard ⁸, Claude Bachmeyer ⁹, Bruno Gombert ¹⁰, Loic Guillevin ¹¹, Maxime Samson ¹² and Benjamin Terrier ¹¹, ¹Department of Internal Medicine, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Paris, France, Paris, France, ²University Hospital of Caen, Caen, France, ³CHU Bordeaux, Bordeaux, France, ⁴Department of Internal Medicine and Infectious Diseases, Centre Hospitalier Universitaire de la Réunion Saint Pierre, Reunion Island, France., Saint-Pierre, France, ⁵Department of internal medicine, CHU Jean Minjoz, Besancon, France, Besancon, France, ⁶Department of Internal Medicine and Clinical Immunology , Hôpital Saint-André, CHU de Bordeaux , Bordeaux , France., Bordeaux, Aquitaine, France, ⁷Department of Internal Medicine and Clinical Immunology , Hôpital Saint-André, CHU de Bordeaux , Bordeaux , France, Bordeaux, France, ⁸CHU Nantes, Nantes, France, ⁹Department of Internal Medicine, Tenon Hospital (AP-HP), Paris, France, Paris, France, ¹⁰Rheumatology Department, Groupe Hospitalier de la Rochelle Ré Aunis, La Rochelle, France., La Rochelle, France, ¹¹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ¹²CHU Dijon, Dijon, France
Background/Purpose: Giant-cell arteritis (GCA) is a large-vessel vasculitis affecting patients >50 years, whose origin remains widely unelucidated. Recent studies demonstrated that myeloid disease-related somatic mutations…
Abstract Number: 2684 • 2019 ACR/ARP Annual Meeting
Real-world Comparative Study of Methotrexate vs Tocilizumab in Patients with Giant Cell Arteritis with Large Vessel Involvement
DIANA PRIETO- PENA¹, Mónica Calderón-Goercke ², Javier Loricera ³, Javier Narváez ⁴, Elena Aurrecoechea ⁵, Ignacio Villa ⁶, Santos Castañeda ⁷, Catalina Gómez-Arango ⁸, Antonio Mera ⁹, Eva Perez Pampín ⁹, Vicente Aldasoro Caceres ¹⁰, N Alvarez Rivas ¹¹, N Fernandez Llanio ¹², María Álvarez del buergo ¹³, Luisa Marena-Rojas ¹⁴, Francisca Sivera ¹⁵, Eva Galindez-Agirregoikoa ¹⁶, Roser Solans-Laqué ¹⁷, Susana Romero-Yuste ¹⁸, Lara Sanchez-Bilbao ¹⁹, Iñigo Gonzalez-Mazon ¹, Isabel Martínez Rodríguez ²⁰, Ignacio Banzo ²⁰, Miguel Angel González-Gay ²¹ and Ricardo Blanco ¹⁹, ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ²Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ³Rheumatology Department. Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ⁵Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, ⁶Hospital de Sierrallana, Torrelavega, Cantabria, Spain, ⁷Rheumatology Department, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, ⁸Hospital Alto Deba, Mondragon, Pais Vasco, Spain, ⁹Division of Rheumatology, Instituto de Investigación Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, Santiago de Compostela, Spain, ¹⁰Complejo Hospitalario de Navarra, Navarra, Navarra, Spain, ¹¹H. Lucus Augusti, Lugo, Spain, ¹²H. Arnau de Vilanova, Lerida, Spain, ¹³Hospital Río Carrión, Palencia, Castilla y Leon, Spain, ¹⁴Hospital La Mancha Centro, Alcázar de San Juan, Castilla-La Mancha, Spain, ¹⁵Hospital General Universitario de Elda, Elda, Spain, ¹⁶Hospital de Basurto, Bilbao, Pais Vasco, Spain, ¹⁷Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain., Barcelona, Catalonia, Spain, ¹⁸Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, ¹⁹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ²⁰Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²¹Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most common large vasculitis in elderly patients. According to previous studies, 50% of patients with GCA in whom…
Abstract Number: 767 • 2019 ACR/ARP Annual Meeting
Outcome Measures in Large-Vessel Vasculitis: Relationships Between Patient, Physician, Imaging, and Laboratory-Based Domains
Casey A. Rimland¹, Kaitlin Quinn ², Joel S. Rosenblum ³, Mollie Schwartz ⁴, K Bates Gribbons ⁵, Elaine Novakovich ⁶, Antoine Sreih ⁷, Peter Merkel ⁷, Mark A. Ahlman ⁸ and Peter C. Grayson ⁹, ¹National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, Chapel Hill, NC, ²Georgetown University Hospital/National Institutes of Health, Washington, DC, ³National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, Bethesda, MD, ⁴University of Maryland, Baltimore, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶National Institutes of Health, Bethesda, MD, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: Large-vessel vasculitis (LVV) is characterized by inflammation of the aorta and its major branches. The most common forms of LVV include giant cell arteritis…
Abstract Number: 2660 • 2019 ACR/ARP Annual Meeting
Rationalizing the Use of MRI of the Scalp Arteries in the Diagnosis of Giant Cell Arteritis Through Multivariable Predictive Modelling
Mats Junek¹, Angela Hu ², Karen Beattie ³, Kimberly Legault ³, Stephanie Garner ⁴, Ryan Rebello ³ and Nader A. Khalidi ³, ¹McMaster University, Oakville, ²University of Toronto, Toronto, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴McMaster University, Hamilton, Canada
Background/Purpose: It has been historically difficult to develop effective diagnostic strategies and criteria in giant cell arteritis (GCA). While temporal artery biopsy was previously thought…
Abstract Number: 2685 • 2019 ACR/ARP Annual Meeting
Factors Contributing to Capturing Positive Findings on Temporal Artery Biopsy: An Australian Experience from Two Rheumatology Referral Centers
Victor Yang ¹, Benjamin Sutu ², Christopher McMaster ³, Claire Owen ¹, Alexander Strathmore ⁴, Gene-Siew Ngian ², Shereen Oon ⁴, Jessica Leung ¹, Ian Wicks ⁵, Russell Buchanan ¹ and David Liew¹, ¹Austin Health, Heidelberg, Victoria, Australia, ²Melbourne Health, Parkville, Victoria, Australia, ³Austin Health, Melbourne, Victoria, Australia, ⁴Melbourne Health, Melbourne, Victoria, Australia, ⁵Melbourne Health, Parkville, Australia
Background/Purpose: Temporal artery biopsy (TAB) is widely recognised as the diagnostic gold standard for GCA, despite having a poor sensitivity due to the presence of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].